APC
BDTX icon

Aspire Private Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Aspire Private Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed – – 613
2022
Q2 		$0 Hold
200
– – ﹤0.01% 608
2022
Q1 		$1K Hold
200
– – ﹤0.01% 531
2021
Q4 		$1K Hold
200
– – ﹤0.01% 571
2021
Q3 		$2K Hold
200
– – ﹤0.01% 477
2021
Q2 		$2K Buy
+200
New +$3.95K ﹤0.01% 480

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aspire Private Capital's BDTX Position: Q3 2022 in Review

Aspire Private Capital sold out of Black Diamond Therapeutics (BDTX) in Q3 2022, closing a stake of 200 shares.

Aspire Private Capital first reported a position in BDTX in Q2 2021 and held it in 5 quarters. The position peaked at $2K in Q3 2021. 69 funds tracked by Wall St. Rank hold BDTX as of Q3 2022.

  • Aspire Private Capital reported no remaining Black Diamond Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Aspire Private Capital sold 200 Black Diamond Therapeutics shares in Q3 2022.
  • Aspire Private Capital first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 5 quarters.
  • Aspire Private Capital's Black Diamond Therapeutics position peaked at $2K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2022.

Based on Aspire Private Capital's 13F filing for Q3 2022, filed 10 Nov 2022.